Nuformix
NFX · Main Market · Health Care · mcap £3.6m · 0.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 25 Aug 26 | Board change | Appointment of Chairman
Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Tim Metcalfe as Non-Executive Chairman and a |
−3.6% |
| 19 Aug 26 | NXP002 Development Update
Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to provide an update on progress with NXP002, the Company's lead programme |
+32.1% | |
| 28 May 26 | Results | Half-year Results
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its unaudited results for the six months ended 31 March 2026. |
−2.9% |
| 31 Mar 26 | Routine | Total Voting Rights | |
| 11 Mar 26 | Fundraise | £1.0 million Placing
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a placing (the "Placing") to raise gross proceeds of £1.0 million throug |
−25.0% |
| 10 Mar 26 | Confirmation of US ODD for NXP002 in IPF
Confirmation of US Orphan Drug Designation for NXP002 Programme in IPF |
+15.4% | |
| 03 Mar 26 | Routine | Result of AGM | |
| 05 Feb 26 | Routine | Posting of Annual Report and Notice of AGM | |
| 27 Jan 26 | Results | Final Results
Annual Results for the period ended 30 September 2025 |
−15.8% |
| 28 Nov 25 | Routine | Total Voting Rights | |
| 12 Nov 25 | Update re. US FDA ODD Application
US FDA Orphan Drug Designation Application for NXP002 Programme in IPF |
−15.2% | |
| 12 Nov 25 | Results | Results of Underwritten Open Offer
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the results of its underwritten Open Offer to Qualifying Shareholders w |
−15.2% |
| 28 Oct 25 | Fundraise | Underwritten Open Offer
Underwritten Open Offer at 0.2p per Open Offer Share to raise £228,081 |
−1.5% |
| 10 Oct 25 | Change of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the appointment of Kreston Reeves Audit LLP ("Kreston Reeves Audit") as |
−5.4% |
Company filings. Not investment advice.